Background
Migraine is one of the most common complaints seen in primary practice [1, 2] , with recent publications reporting an incidence in the general population of approximately 8% in men and 12-15% in women [1] . This neurological condition is characterized by recurrent headache attacks with associated symptoms, such as nausea, phonophobia and photophobia. In 10-20% of patients, the headache is preceded by visual disturbances, known as the migraine aura. Migraine is also associated with significant socioeconomic and quality-of-life impacts [3, 4] ; in fact, the World Health Organization has ranked migraine 19 th in the world among diseases causing disability [5] . The main aims of acute migraine treatment are rapid pain relief, improvement of associated symptoms and prevention of migraine recurrence within 24 hours [6] . However, treatment is complicated by the complex and multifactorial pathophysiology of migraine [7, 8] .
Ergotamine had been the mainstay of acute migraine treatment for more than 60 years, and is still widely prescribed despite the wide availability of triptans [9] and its drawbacks, which include a lack of receptor specificity and less than favourable tolerability profile [10, 11] . Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat migraine attacks and can also be combined with antiemetics to aid relief of the associated nausea symptoms [10, 12] . Migraine treatment guidelines recommend NSAIDs as first-line therapy in most migraine patients [13] , and triptans (5-hydroxytryptamine 1B/1D agonists) [12, 14] are recommended for moderate-to-severe acute migraine attacks that fail to respond to NSAIDs [13] , as they are highly effective in treating pain and aborting the migraine attack [15] . Currently, however, the use of triptans is low with only 10-15% of migraine patients in Denmark and the UK being prescribed a triptan [16] . The first triptan to be commercially available was sumatriptan [14, 17, 18] . This agent is still the most commonly prescribed of the triptans [19] , although seven drugs in this class are now available. Opioid analgesics are used commonly in emergency departments [20] , but because of their potential for dependence and medication-overuse headache they are not recommended for migraine treatment, despite some efficacy in relieving migraine pain [21] .
The efficacy of triptans in acute migraine therapy arises from their action on the trigeminovascular complex, related to their activity at the 5-HT 1B/1D receptor [22] . Most likely, it is their selective constrictor effect on the cerebral vessels that is important in mediating their migraine-abortive efficacy [22] . In animal studies, sumatriptan has been shown to inhibit neurogenic inflammation [23, 24] . Whether neurogenic inflammation is involved in migraine is unknown, but some studies have reported increased levels of calcitonin gene-related peptide in the external jugular vein during migraine attacks, an increase which is reversible with sumatriptan [23, 25] . Also, a clinical problem has emerged with the use of triptans, in that there is a high incidence of migraine pain recurrence after initially high efficacy [9] . As such, combination drug therapy with a triptan and an NSAID may be a more effective migraine treatment strategy [26, 27] .
Despite recent developments in acute migraine treatment research, many primary-care physicians have not altered their approach to migraine management, with most migraine attacks still being treated exclusively with over-the-counter products [16] , despite increases in physician-diagnosed migraine [28] .
Review of the evidence
In this review, we examine the best recent evidence for the efficacy of medical therapy for acute migraine, focusing on the primary pain-centred clinical outcomes, as recommended by the International Headache Society (IHS) [29] .
Search strategy
English language articles were searched in November 2007, using Medline (2002 to date), Embase (2002 to date), the Cochrane Library and Odyssey (a proprietary database of Wolters Kluwer Health). Search terms were: ('frovatriptan' OR 'sumatriptan' OR 'almotriptan' OR 'eletriptan' OR 'rizatriptan' OR 'naratriptan' OR 'zolmitriptan' OR 'NSAIDs' OR 'ergot derivatives' OR 'opiates' OR 'barbiturates' OR 'dopamine antagonists' OR 'aspirin' OR 'paracetamol') AND 'migraine' AND ('treatment' OR 'acute').
Inclusion/exclusion criteria
Inclusion/exclusion criteria were based on the IHS guidelines for design of clinical trials of acute migraine treatment, which indicate that clinical trials should recruit adult patients meeting the strict IHS criteria for diagnosis of migraine with or without aura with a disease duration of at least 1 year [29] . Included were randomized, actively controlled, parallel-group or crossover trials of the abovenamed drugs in !100 patients aged 18-65 years experiencing at least 1 migraine attack (with or without aura) per month for at least 1 year, in which the primary or coprimary endpoint was the proportion of patients pain-free within 2 h and/or headache relief within 2 h and/or use of rescue medication. Trials had to include treatment of at least one migraine attack with active treatment; systematic reviews or meta-analyses of randomized, actively controlled trials (RCTs) meeting the above inclusion criteria were also eligible for inclusion. Papers published in abstract form only were included in this review provided the abstract included the necessary data to assess the criteria for inclusion. In addition, papers not published in the English language, trials conducted in patients with menstrual migraine and studies that did not pre-specify a primary endpoint complete with a power calculation were excluded.
Results
Overall, 11 RCTs met the inclusion criteria specified for this review [9, 12, 14, 18, 27, [30] [31] [32] [33] [34] , and a publication that reported the results of two identically-designed RCTs was allowed entry due to its importance in this therapeutic area despite recruiting patients with a migraine history shorter than that specified in our inclusion criteria (!6 months) [26] . The treatment regimens and primary endpoint results are summarized in Table 1 . No systematic reviews or meta-analyses fitting the inclusion criteria were identified, and no abstracts published in conference proceedings reported sufficient patient selection data to meet the inclusion criteria of this review. Of those trials that were excluded, the majority failed to specify detailed patient inclusion criteria or recruited patients with a migraine history that was shorter than 1 year, despite using IHS guidelines for migraine diagnosis.
Comparative triptan trials
Few direct head-to-head trials of triptans have been published in the last 5 years, with the majority of published data being limited to comparisons of one of the other triptans with sumatriptan, the first commercially available triptan [14, 18] . Two of the RCTs included in our analysis directly compared two triptans in the acute treatment of migraine, the efficacy of which was shown to be equivalent [18, 32] . Both studies were double-blinded with a parallel design; Dowson et al. compared almotriptan 12.5 and 25 mg with sumatriptan 100 mg and placebo [32] , while Goadsby and colleagues randomized patients to almotriptan 12.5 mg or zolmitriptan 2.5 mg [18] . In both studies, no significant differences between almotriptan and the comparator drugs were observed; Dowson et al. reported a 2 h pain-relief (defined as a reduction in migraine pain intensity from severe-to-moderate pain to mild or no pain) rate of approximately 57% in almotriptan recipients compared with 64% of sumatriptan-treated patients [32] . Both doses of almotriptan were confirmed to be statistically equivalent to sumatriptan, as the 90% confidence interval (CI) was inside the pre-specified range of equivalence (-0.15, 0.15). Almotriptan did, however, offer a tolerability advantage over sumatriptan, with significantly fewer almotriptan 12.5 mg than sumatriptan recipients reporting adverse events (9% vs. 22% of patients; P < 0.001); almotriptan 25 mg and sumatriptan were similarly tolerated. It is interesting to note, that although these recent studies found no significant difference, an older study (published in 2001 and therefore not fitting the inclusion criteria for this review) did show a Patients treated 2 consecutive migraine attacks.
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(continued overleaf ) significant difference in the 2 h pain-free rate in favour of almotriptan (25% vs. 18%; P < 0.05) [35] .
The respective response rate (proportion of patients painfree at 2 h) was 44% with almotriptan versus 48% with zolmitriptan in the Goadsby et al. analysis, a nonsignificant difference [18] . This primary endpoint was extracted from a composite primary endpoint of sustained pain-free status first reported at 2 h plus no adverse events (SNAE) used in the latter analysis. With regard to this overall endpoint, which was assessed over 24 h, the two triptans were still not significantly different in their efficacy; SNAE was observed in 29% of almotriptan and 32% of zolmitriptan recipients. Similarly to the Dowson et al. report, this trial also found a tolerability advantage for almotriptan, with almotriptan recipients reporting a significantly (P < 0.05) lower incidence of triptan-associated general and central nervous system adverse events (11% and 6% of patients) than zolmitriptan (16% and 9%, respectively). These data indicate that while triptans may demonstrate similar efficacy profiles, there are sizeable tolerability differences between the specific agents within this drug class, which may be applicable to primary patient care.
Indomethacin/caffeine/prochlorperazine versus triptans
Indomethacin/caffeine/prochlorperazine (IndoProCaf), a combination of caffeine with an NSAID and an antiemetic, is the most commonly used pharmacological migraine therapy in Italy [14, 33] . This fixed-combination therapy was compared with sumatriptan in two of the trials that met inclusion criteria for entry to this review [14, 33] . In the earlier, open-label, randomized trial reported by Di Monda and colleagues, fixed-combination indomethacin 25 mg, caffeine 75 mg and prochlorperazine 4 mg suppositories produced a significantly higher pain-free at 2 h rate than sumatriptan (49% vs. 34% of patients; P < 0.01) [14] . IndoProCaf also proved superior to sumatriptan with regard to some of the secondary endpoints assessed, such as presence of nausea at 2 h (26% with IndoProCaf vs. 33% with sumatriptan; P < 0.05) and sustained pain-free response, defined as pain-free at 2 h and no use of rescue medication or migraine pain relapses within 48 h (44% vs. 30%, respectively; P < 0.01). The authors commented that the significant nausea improvement observed in IndoProCaf recipients was most likely due to the antiemetic effect of prochlorperazine.
The later study by Sandrini et al., which was doubleblinded, found that there was no significant difference in the pain-free at 2 h rate between patients treated with oral fixed-dose indomethacin 25 mg, caffeine 75 mg and prochlorperazine 2 mg, and those who received oral Combination therapy with sumatriptan/naproxen sodium was significantly more effective than both sumatriptan and naproxen sodium (both P 0.01) administered alone.
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In this study, the primary endpoint was the sustained pain response rate, defined as patients having no greater than mild pain at 2 h, no use of escape medication at 24 h and no recurrence of moderate or severe pain at 24 h. sumatriptan (34% vs. 37%; 95% CI for odds ratio: 0.57-1.28) [33] . In this study, patients treated two consecutive migraine attacks, and results were presented for each attack separately, as well as mean data for both attacks. Despite a lack of significance for the primary endpoint, IndoProCaf showed significant benefits compared with sumatriptan therapy for some secondary endpoints: in the first of two migraine attacks which were treated with study medication, IndoProCaf produced significantly higher rates of pain-free (46% vs. 23%). However, no significant differences between the treatment groups were observed for this or any other parameters for the second treated migraine attack, or for the average of both attacks treated. These results, taken together with the lower IndoProCaf dose administered in the Sandrini et al. trial, point towards comparability of this fixedcombination therapy to sumatriptan, which is currently considered to be the gold standard of acute migraine treatment [36] . Further research into the efficacy of IndoProCaf compared to that of triptans, using appropriate dosing schedules, is needed to confirm any differences in treatment efficacy with oral administration.
Triptans versus aspirin and NSAIDs
The majority of the trials meeting inclusion criteria for our analysis assessed the migraine abortive efficacy of aspirin, NSAIDs and/or triptans [12, 27, 30, 31, 34] , with overall results indicating that NSAIDs are generally as effective as the triptans, and that the various NSAIDs produce similar results. For example, in a large study, Dib et al. found that pain relief at 2 h was observed in similar proportions of migraines treated with ketoprofen 75-150 mg ($62%) and those dosed with zolmitriptan (67%), corresponding to a lower limit of the CI of -12.3%; however, non-inferiority of ketoprofen compared with zolmitriptan could not be confirmed as the clinical equivalence limit was set a priori at a lower limit of the CI of -10% [30] . In 2004, Diener et al.
reported that sumatriptan was associated with similar 2 h pain-relief rates (defined as a reduction in pain intensity from grade 3-2 to grade 1-0) as effervescent aspirin tablets (56% vs. 53% of patients) and ibuprofen (60%) [31] . The addition of the antiemetic metoclopramide to aspirin tablets in a trial by Geraud et al. resulted in a migraine pain improvement (from severe or moderate to mild or no pain) rate that was similar to that achieved in zolmitriptan recipients (both $33% of patients) [12] .
Generally, the various NSAIDs are associated with similar migraine abortive efficacy; for example, Saper et al. published data in 2006 showing similar 2 h painrelief rates in patients receiving rofecoxib 25 or 50 mg ($61% of patients) as those reported in ibuprofen recipients (58%) [34] , and the above-mentioned Diener et al.
trial showed no clinical differences between effervescent aspirin and ibuprofen [31] .
Although triptan therapy is considered to be the goldstandard migraine treatment [36] , the results of a trial conducted by Smith and colleagues in 2005 with encapsulated sumatriptan indicate that fixed-combination sumatriptan/naproxen sodium 50/500 mg is more effective in acute migraine treatment than either agent administered as monotherapy [27] . Headache response at 2 h was recorded significantly more frequently in sumatriptan/ naproxen sodium recipients (65%) than in patients dosed with either sumatriptan or naproxen sodium alone (49% and 46%; both P 0.01). In this trial, headache response at 2 h was assessed as part of the composite primary endpoint, sustained pain response, defined as pain no greater than mild at 2 h, no use of rescue medication within 24 h and no recurrence of moderate or severe pain within 24 h postdose; again, fixed-combination sumatriptan/naproxen sodium elicited this response in significantly more patients than either treatment given alone (29% vs. 25% and 17%, respectively; both P < 0.001). Smith et al. proposed that this advantage is due to the multimechanism approach afforded by sumatriptan/naproxen sodium therapy which combines the actions of both a triptan and a NSAID, compared with the single-pronged attack of monotherapy.
The migraine-abortive superiority of fixed-combination sumatriptan/naproxen sodium 85/500 mg over its components was confirmed in a 2007 publication by Brandes et al. [26] . This article reported the results of two identically designed trials, which together randomized a total of 3413 migraine patients. In both studies, fixed-combination sumatriptan/naproxen sodium led to a significantly higher 2 h headache-relief rate, defined as pain reduction from moderate or severe to mild or no pain, than sumatriptan monotherapy (65% vs. 55% of patients, P ¼ 0.009 in study 1; 57% vs. 50%, P ¼ 0.03 in study 2). While the clinical relevance of a 7-10% increase in the headacherelief rate can be questioned, this large report highlights the fact that the pharmacological effect is certainly present. It should be pointed out that the Smith et al. [27] and Brandes et al. [26] trials used different sumatriptan doses (50 mg vs. 85 mg, respectively). While this dose difference is not large, it may impose implications on the comparability of these trial results.
Triptans better than caffeine/ergotamine
Two of the studies included in our review confirmed the superior efficacy of triptans over caffeine/ergotamine in patients with acute migraine [9, 37] . The first of these trials, conducted by Diener et al. [9] , yielded one of the biggest differences observed between active treatments in our analysis: migraine pain improvement from severe or moderate to mild or no pain at 2 h was significantly more frequently observed in patients treated with eletriptan (54% and 68% of eletriptan 40 and 80 mg recipients) than those receiving caffeine/ergotamine (33%; P 0.001 for both eletriptan doses). The second of these trials compared the migraine-abortive efficacy of caffeine/ergotamine with almotriptan [37] . Again, the triptan proved to be more effective than caffeine/ ergotamine, with significantly more almotriptan recipients becoming pain-free at 2 h post-dose (21% vs. 14% of caffeine/ergotamine recipients; P < 0.05). A similar result was observed for the 2 h pain-relief rate (58% vs. 45%, respectively; P < 0.01).
The triptans and ergotamine both have an agonistic action on the 5-HT 1B/1D receptor and given in equipotent doses, the triptans and ergotamine most likely have similar efficacy in the acute treatment of migraine but ergotamine will result in more adverse events [22] .
Conclusion
The majority of RCTs conducted in patients with acute migraine do not follow IHS guidelines for patient enrolment and despite a wide array of data published in this field, few trials met the strict inclusion criteria for this review. The results of recently published (!2002) RCTs, which constitute the best current evidence, indicate that triptans and NSAIDs are similarly effective in the treatment of acute migraine. While the various triptans currently available on the market are similarly effective, among newer triptans, almotriptan is associated with a better tolerability profile than sumatriptan, the first commercially available, and most widely used, agent in this class. Fixed-combination therapy with IndoProCaf is probably as effective as sumatriptan, but more data from large, well controlled trials with improved dosing schedules are needed to confirm this. Finally, multi-targeted therapy aiming at both the cerebrovascular and the presumed inflammatory processes in migraine, such as fixedcombination sumatriptan/naproxen sodium, is more effective than administration of either the triptan or NSAID alone. These findings are generally consistent with published migraine treatment practice guidelines [13, 38] .
